Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer

  • Technology appraisal guidance
  • TA693
  • Published: 

This guidance has been updated and replaced by NICE technology appraisal guidance 946.